The drug they said was impossible: CYT-108

Modern medicine has spent decades — and hundreds of billions of dollars — trying to cure osteoarthritis. But they failed. Every drug on the market just masks the pain while cartilage continues to deteriorate. That's not a cure. It's a cover-up.

Which is why Cytonics caught my attention. This small medical startup discovered a protein your body naturally produces to protect joints — then genetically engineered a version 200% more potent. They built a therapy that goes after the root cause of the disease, not just the symptoms. And the early data backs it up — Phase 1 human trials finished with zero adverse events, and more than 10,000 patients have already found relief through the first-generation treatment.

The smart money sees it too. Rener Gracie — third-generation BJJ master whose family invented the sport — just put seven figures behind the company. So did his wife Eve. These are people whose careers depend on healthy joints.

Cytonics opened a Reg CF offering, and 7,000 investors are already in.

Click here to review the deal before it closes.

Disclaimer: This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://invest.cytonics.com. Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal.